HIV Drug Resistance Patterns and Characteristics Associated with Clinically Significant Drug Resistance among Children with Virologic Failure on Antiretroviral Treatment in Kenya: Findings from the Opt4Kids Randomized Controlled Trial
Related Experiment Video
Updated: Jul 12, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Lisa Abuogi1, Patrick Oyaro2,3, Garoma Wakjira4
1Department of Pediatrics, University of Colorado, Denver, CO 80045, USA.
Insights
Drug resistance is common in children with HIV on treatment in Kenya. Prior treatment failure and shorter time on ART increase the risk of drug resistance, highlighting the need for targeted testing.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Molecular Virology
Background:
- Increasing HIV drug resistance (DR) poses a significant challenge for children with HIV (CHIV) on antiretroviral treatment (ART).
- Effective management of pediatric HIV requires understanding the prevalence and drivers of drug resistance.
Purpose of the Study:
- To describe drug resistance mutations and identify factors associated with clinically significant DR in CHIV in Kenya.
- To evaluate the utility of point-of-care viral load testing and targeted genotypic drug resistance testing.
Main Methods:
- A randomized controlled trial involving 704 CHIV (ages 1-14) in Kisumu County, Kenya.
- Intervention group received point-of-care viral load testing every three months; both groups underwent targeted genotypic drug resistance testing (DRT) for virologic failure.
- Logistic regression models were used to identify factors associated with major drug resistance.
Main Results:
- Of 106 children with DRT results, 100% had detectable drug resistance mutations.
- 88% had major mutations, and 54% exhibited dual-class resistance.
- History of virologic failure (VF) in the prior 2 years (aOR 11.1) and <2 years on ART at enrollment (aOR 2.2) were associated with increased odds of major DR.
Conclusions:
- Drug resistance is highly prevalent among CHIV with VF in Kenya.
- Identifying children at higher risk for DR through factors like prior VF and time on ART can guide prioritization for DRT.
- Point-of-care testing strategies may improve management of pediatric HIV.
Abstract:
Increasing HIV drug resistance (DR) among children with HIV (CHIV) on antiretroviral treatment (ART) is concerning. CHIV ages 1-14 years enrolled from March 2019 to December 2020 from five facilities in Kisumu County, Kenya, were included. Children were randomized 1:1 to control (standard-of-care) or intervention (point-of-care viral load (POC VL) testing every three months with targeted genotypic drug resistance testing (DRT) for virologic failure (VF) (≥1000 copies/mL)). A multidisciplinary committee reviewed CHIV with DRT results and offered treatment recommendations. We describe DR mutations and present logistic regression models to identify factors associated with clinically significant DR. We enrolled 704 children in the study; the median age was 9 years (interquartile range (IQR) 7, 12), 344 (49%) were female, and the median time on ART was 5 years (IQR 3, 8). During the study period, 106 (15%) children had DRT results (84 intervention and 22 control). DRT detected mutations associated with DR in all participants tested, with 93 (88%) having major mutations, including 51 (54%) with dual-class resistance. A history of VF in the prior 2 years (adjusted odds ratio (aOR) 11.1; 95% confidence interval (CI) 6.3, 20.0) and less than 2 years on ART at enrollment (aOR 2.2; 95% CI 1.1, 4.4) were associated with increased odds of major DR. DR is highly prevalent among CHIV on ART with VF in Kenya. Factors associated with drug resistance may be used to determine which children should be prioritized for DRT.
Related Concept Videos
Retrovirus Life Cycles
Viral Mutations
Retroviruses
Immunodeficiency Diseases
There are three main causes of immunodeficiency...

